118 related articles for article (PubMed ID: 11576359)
1. Correlates of acute renal failure in patients receiving parenteral amphotericin B.
Bates DW; Su L; Yu DT; Chertow GM; Seger DL; Gomes DR; Platt R
Kidney Int; 2001 Oct; 60(4):1452-9. PubMed ID: 11576359
[TBL] [Abstract][Full Text] [Related]
2. Acute renal failure with amphotericin B in lipid emulsion.
Gales MA; Gales BJ; Alford KM
Ann Pharmacother; 1996 Sep; 30(9):1036. PubMed ID: 8876871
[No Abstract] [Full Text] [Related]
3. Mortality and costs of acute renal failure associated with amphotericin B therapy.
Bates DW; Su L; Yu DT; Chertow GM; Seger DL; Gomes DR; Dasbach EJ; Platt R
Clin Infect Dis; 2001 Mar; 32(5):686-93. PubMed ID: 11229835
[TBL] [Abstract][Full Text] [Related]
4. Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors.
Hingorani SR; Guthrie K; Batchelder A; Schoch G; Aboulhosn N; Manchion J; McDonald GB
Kidney Int; 2005 Jan; 67(1):272-7. PubMed ID: 15610251
[TBL] [Abstract][Full Text] [Related]
5. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
[TBL] [Abstract][Full Text] [Related]
6. Are there risk factors for acute renal failure in adult patients using deoxycholate amphotericin B?
Tuon FF; Koenig F; Jacometto D; Rocha JL
Rev Iberoam Micol; 2013 Jan; 30(1):21-4. PubMed ID: 22995903
[TBL] [Abstract][Full Text] [Related]
7. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
Maharom P; Thamlikitkul V
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
[TBL] [Abstract][Full Text] [Related]
8. Amphotericin B-related nephrotoxicity in low-risk patients.
Berdichevski RH; Luis LB; Crestana L; Manfro RC
Braz J Infect Dis; 2006 Apr; 10(2):94-9. PubMed ID: 16878259
[TBL] [Abstract][Full Text] [Related]
9. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
Wade RL; Chaudhari P; Natoli JL; Taylor RJ; Nathanson BH; Horn DL
Diagn Microbiol Infect Dis; 2013 Jul; 76(3):361-7. PubMed ID: 23774005
[TBL] [Abstract][Full Text] [Related]
10. [Amphotericin B deoxycholate prescription and adverse events in a Chilean university hospital].
Quinteros A R; Fica C A; Abusada A N; Muñoz C L; Novoa M C; Gallardo A C
Rev Chilena Infectol; 2010 Feb; 27(1):25-33. PubMed ID: 20140311
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.
Hamill RJ; Sobel JD; El-Sadr W; Johnson PC; Graybill JR; Javaly K; Barker DE
Clin Infect Dis; 2010 Jul; 51(2):225-32. PubMed ID: 20536366
[TBL] [Abstract][Full Text] [Related]
12. Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment.
Alvarez-Lerma F; Soriano MC; Rodríguez M; Catalán M; Llorente AM; Vidart N; Garitacelaya M; Maraví E; Fernández E; Alvarado F; López M; Alvarez-Sánchez B; Espinosa J; Quintana E;
Rev Esp Quimioter; 2012 Sep; 25(3):206-15. PubMed ID: 22987267
[TBL] [Abstract][Full Text] [Related]
13. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
Rieger CT; Dittmer M; Ostermann H
Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
[TBL] [Abstract][Full Text] [Related]
14. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study.
Falci DR; da Rosa FB; Pasqualotto AC
Mycoses; 2015 Feb; 58(2):104-12. PubMed ID: 25590436
[TBL] [Abstract][Full Text] [Related]
15. An elevated pro-inflammatory cytokine response is linked to development of amphotericin B-induced nephrotoxicity.
Chai LY; Netea MG; Tai BC; Khin LW; Vonk AG; Teo BW; Schlamm HT; Herbrecht R; Donnelly JP; Troke PF; Kullberg BJ
J Antimicrob Chemother; 2013 Jul; 68(7):1655-9. PubMed ID: 23557927
[TBL] [Abstract][Full Text] [Related]
16. [Pulmonary mucormycosis: benefit of aerosol amphotericin B?].
Furco A; Mouchet B; Carbonnelle M; Vallerand H
Rev Mal Respir; 2001 Jun; 18(3):309-13. PubMed ID: 11468594
[TBL] [Abstract][Full Text] [Related]
17. [Safety of long-term administration of conventional amphotericin B in oncology patients].
Doubek M; Mayer J; Horký D
Cas Lek Cesk; 2002 Mar; 141(5):156-9. PubMed ID: 11998223
[TBL] [Abstract][Full Text] [Related]
18. Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting.
Bes DF; Rosanova MT; Sberna N; Arrizurieta E
Pediatr Infect Dis J; 2014 Aug; 33(8):e198-206. PubMed ID: 24618932
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of the use of liposomal amphotericin B].
González Martínez M; Mariño Martínez C; Baldominos Utrilla G; Fernández Martínez MN
Rev Iberoam Micol; 2014; 31(2):109-13. PubMed ID: 23711815
[TBL] [Abstract][Full Text] [Related]
20. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
Aguado JM; Lumbreras C; González-Vidal D;
Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
